Press Releases

InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update

-CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority  for Health (HAS) regarding reimbursement in France- -$37.1 million in cash, cash equivalents and short-term bank deposits as of September 30, 2021, provides runway into first half of 2023- -Management to host Call & Webcast Today, November… Read More

InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions

Tel Aviv, Israel— November 3, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced that results from the investigator-initiated SIBERIA randomized clinical trial of CGuard EPS, that evaluated the peri-procedural and 30-day silent brain infarcts… Read More

InspireMD to Report Third Quarter 2021 Financial Results on November 9, 2021 and Provide Corporate Business Update -Earnings Conference Call to be held Tuesday, November 9, 2021, at 8:30 a.m. ET-

Tel Aviv, Israel— October 26, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces it will report third quarter 2021 financial results on Tuesday, November 9, 2021, before the market opens.  Management will host a… Read More

InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health

Tel Aviv, Israel— October 13, 2021 – InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS stent system has received a positive opinion from the National Commission for the Evaluation of… Read More

InspireMD Announces Strong Second Quarter 2021 Financial Results

Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET Tel Aviv, Israel— August 10, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating… Read More

InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS

Tel Aviv, Israel— July 23, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiation of enrollment and successful completion of the first cases of the Company’s U.S. registration C-Guardian trial of CGuard EPS…. Read More

InspireMD to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

Tel Aviv, Israel— June 2, 2021 – InspireMD, Inc. (Nasdaq-CM: NSPR) developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), announced today that Chief Executive Officer Marvin Slosman will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8… Read More

InspireMD Announces Warrants Exchange Listing Transfer to Nasdaq

Tickers to be NSPRW and NSPRZ   Tel Aviv, Israel— May 27, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced the Company’s warrants, NSPR.WS and NSPR.WSB, currently traded on the NYSE: American, have… Read More

InspireMD Commences Trading on Nasdaq-CM

Ticker to remain NSPR    Tel Aviv, Israel— May 21, 2021 – InspireMD, Inc. (Nasdaq-CM: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by Carotid Artery Disease (CAD), today announced that the Company’s shares will commence trading on The Nasdaq Capital Market (“Nasdaq-CM”), today, May 21, 2021, under… Read More